Abstract
We have studied growth hormone (GH), insulin (I), glucagon (Gl) and glucose in basal conditions, after somatostatin (SS) (3 μg/ml) and Phe-4-SS (0.75 μg/ml) infusion and IV bolus of the latter in 3 acromegalic patients. In two patients, Phe-4-SS inhibited glucagon and growth hormone secretion in a similar way to SS, without modifying insulin secretion. These effects were short-lived and ceased after the infusion was stopped. From these results it appears that Phe-4-SS is both more potent and more specific than SS with respect to inhibition of GH and glucagon release, but it does not have prolonged biological action. Lack of suppression of GH by SS or Phe-4-SS in the acromegalic patient with post-surgical recurrence of the disease could be due to the existence of receptor abnormalities, and suggests a diversity in the physiopathology of the disease.
| Original language | English |
|---|---|
| Pages (from-to) | 432-444 |
| Number of pages | 13 |
| Journal | Research Communications in Chemical Pathology and Pharmacology |
| Volume | 45 |
| Issue number | 3 |
| State | Published - Nov 15 1984 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Toxicology
- Pharmacology
Cite this
Inhibition of growth hormone and glucagon release by Phe-4-somatostatin in patients with acromegaly. / Charro, A. L.; Cabranes, J. A.; Lafuente, A.; Diaz-Salgado, C.; Cordero, M.; Almoguera, I.; Comaru-Schally, A. M.; Meyers, C. A.; Coy, D. H.; Schally, Andrew V.
In: Research Communications in Chemical Pathology and Pharmacology, Vol. 45, No. 3, 15.11.1984, p. 432-444.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Inhibition of growth hormone and glucagon release by Phe-4-somatostatin in patients with acromegaly
AU - Charro, A. L.
AU - Cabranes, J. A.
AU - Lafuente, A.
AU - Diaz-Salgado, C.
AU - Cordero, M.
AU - Almoguera, I.
AU - Comaru-Schally, A. M.
AU - Meyers, C. A.
AU - Coy, D. H.
AU - Schally, Andrew V
PY - 1984/11/15
Y1 - 1984/11/15
N2 - We have studied growth hormone (GH), insulin (I), glucagon (Gl) and glucose in basal conditions, after somatostatin (SS) (3 μg/ml) and Phe-4-SS (0.75 μg/ml) infusion and IV bolus of the latter in 3 acromegalic patients. In two patients, Phe-4-SS inhibited glucagon and growth hormone secretion in a similar way to SS, without modifying insulin secretion. These effects were short-lived and ceased after the infusion was stopped. From these results it appears that Phe-4-SS is both more potent and more specific than SS with respect to inhibition of GH and glucagon release, but it does not have prolonged biological action. Lack of suppression of GH by SS or Phe-4-SS in the acromegalic patient with post-surgical recurrence of the disease could be due to the existence of receptor abnormalities, and suggests a diversity in the physiopathology of the disease.
AB - We have studied growth hormone (GH), insulin (I), glucagon (Gl) and glucose in basal conditions, after somatostatin (SS) (3 μg/ml) and Phe-4-SS (0.75 μg/ml) infusion and IV bolus of the latter in 3 acromegalic patients. In two patients, Phe-4-SS inhibited glucagon and growth hormone secretion in a similar way to SS, without modifying insulin secretion. These effects were short-lived and ceased after the infusion was stopped. From these results it appears that Phe-4-SS is both more potent and more specific than SS with respect to inhibition of GH and glucagon release, but it does not have prolonged biological action. Lack of suppression of GH by SS or Phe-4-SS in the acromegalic patient with post-surgical recurrence of the disease could be due to the existence of receptor abnormalities, and suggests a diversity in the physiopathology of the disease.
UR - http://www.scopus.com/inward/record.url?scp=0021203196&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021203196&partnerID=8YFLogxK
M3 - Article
VL - 45
SP - 432
EP - 444
JO - Research Communications in Molecular Pathology and Pharmacology
JF - Research Communications in Molecular Pathology and Pharmacology
SN - 0034-5164
IS - 3
ER -